|Awarded On||August 16, 2017|
|Title||A Novel Chemical Strategy to Target EGFR for Destruction|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Hai Rao|
|Cancer Sites||Breast, Lung and Bronchus, Thyroid|
Resistance arises when tumors often adapt to the drug and manage to find alternate routes to resume cell growth. Selective proteolysis of a key regulator allows for rapid adjustments of its concentration and has emerged as a promising therapeutic means for cancer. The goal of this work is to develop a novel approach to modulate protein stability that would eliminate, rather than simply inhibit, the target protein, which would overcome drug resistance, a common shortcoming of targeted therapies. Specifically, we will design and evaluate novel cell permeable compounds that exploit the cell’s own proteasome-mediated degradation pathway to specifically eliminate the epidermal growth factor rece...